Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma. | PHASE1 | COMPLETED | 25 | — | — | Jan 1, 2013 | Dec 1, 2016 | Jul 26, 2022 | 3 | France |
Decrease of TF2 and IMP- 288 molar doses and variation of pretargeting interval will be performed in 4 to 5 cohorts of 3 patients, receiving 120 to 30 nmol of TF2 and 6 à 1.5 nmol of peptides 1 to 3 days apart. A last cohort (number 5 or 6) with optimal conditions will be proposed Blood samples will be obtained after TF2 and 68Ga-IMP-288 injections. Whole-body PET images will be recorded 60 to 120 minutes after 68Ga-IMP-288 injection to assess semiquantitatively tumor targeting and tumor/background ratio.
| Arm | Type | Description |
|---|---|---|
| TF2 antibody/68Ga-IMP-288 | EXPERIMENTAL | TF2 coupled with 68 Ga-IMP-288 |
| Name | Type | Description |
|---|---|---|
| • TF2 and 68 Ga-IMP-288 | DRUG | - |
Inclusion Criteria: * Histological diagnosis of CMT * Calcitonin\> 150 pg / ml * Complete treatment of the primary tumor * at least one detectable lesion more than 10 mm on conventional imaging: bone lesions can be taken into account if they extend outside of the bone and the party extra bone is me...